search
Insight providers: David White, Product Marketing Executive & Susan Hinko, Head of Industrial Relations, TriOptima Clear Path Analysis has put together a report that explores the evolving role of securities lending in a c
Insight provider: Mara Moreno Todos los participantes en el mercado de derivados OTC y sujetos a EMIR tendrán que cumplir con la fecha límite del informe de sus operaciones estipulado por la European Securi
Der CEO des triResolve Service von TriOptima, Raf Pritchard, erläutert die wesentliche Funktion von verlässlichen und automatisierten Systemen im Zusammenhang mit der Abstimmung von OTC-Derivateportfolios und der Unte
1 2 3 4 5
home > resource center > insights
It’s transparency, but not as we know it


Insight providers: Per Sjöberg, Executive Vice President, and Susan Hinko, Global Head of Industry Relations, TriOptima

There is a widely-held belief that the over-the-counter (OTC) derivatives market and the pricing of transactions are too opaque and not accessible to the general public.

Real time reporting and price transparency are viewed as the panacea to solve these problems. Achieving price and position transparency in the OTC derivatives market is an important goal of the new regulatory and legislative initiatives and rule-making currently underway.

Many believe that “real time” reporting of trades will accomplish that transparency while providing significant benefits to market participants. But that belief may be founded on knowledge of the highly liquid, standardized cash and futures markets rather than on the realities of the OTC derivatives market. This is the wrong comparison to be making because the volumes in the OTC markets are significantly smaller and more dispersed.

Not addressing the realities of the OTC markets could seriously undermine a market that plays a vital role in the global financial landscape.

Understanding the size of the interest rate swap market: turnover vs. inventory
In its capacity as the Interest Rate Trade Reporting Repository, TriOptima has been given access to data on interest rate OTC derivatives traded by the G-14* institutions which include the major global OTC derivative dealers. To test the belief that ”real time” reporting will create meaningful, public transparency, TriOptima analyzed the data submitted by the G-14 institutions in June 2010. While the G-14 institutions do not represent the entire OTC derivatives market, they do represent the vast majority of trades.

The Bank of International Settlements, which gathers statistics from the central banks around the world, reported that there was $349,240bn in notional outstanding in interest rate swaps for the second half of 2009. In June 2010, the G-14 reported there were 3m interest rate swaps with a notional value of $332,200bn in the Interest Rate Trade Reporting Repository.

This sounds like a lot to someone not well-acquainted with the OTC markets. But it is important to realize that this is the total inventory of interest rate swaps globally across all currencies and all maturities. This inventory has grown over a long period of time and does not represent turnover or activity in trading.

There are many swaps that actually extend out to 50 years and sit in this inventory. Also, this includes all currencies in which an interest rate swap is traded, currently numbering 56 globally some with only one trade outstanding.

TriOptima analyzed the interest rate swap data submitted for June 2010 and found that the average daily volume in interest rate swaps was 3,600 trades per day across all maturities and all currencies around the globe for the G-14 dealers.

Size vs.trading frequency of interest rate swap transactions
For US dollar interest rate swaps, which is the most actively traded product, an average of 1,200 transactions a day were traded; euro interest rate swaps averaged just 830 trades per day.

To achieve price transparency, it is important to compare apples to apples. But when discussing interest rate swaps, 50 per cent of the daily volume were forward starting (meaning they take effect sometime in the future) or mature on an odd end date (reflecting the customized nature of OTC derivatives).

Only 50 per cent of the daily volume in dollar interest rate swaps was standardized with full year maturities, lending themselves to price comparison. This brings the standardized volume of interest rate swap transactions to a total of 600 per day in all maturities.

In the most liquid full year transaction type, 10-year dollar interest rate swaps, there were only 208 transactions per day in June last year. This means that about 17, 10-year dollar interest rate swap contracts were traded each hour in a 12-hour period. Most of the standardized swaps in other maturities and currencies trade less than 20 contracts per day making a meaningful price comparison between two transactions virtually impossible.

Why have the implications of price transparency for OTC derivatives been difficult to understand? Probably because the turnover data was not publicly available before and because the notional principal outstanding is significant. In the absence of actual data, the reference points for lawmakers and regulators were the cash and futures markets, all of which are high-frequency, standardized markets with a ticker recording trades every second, not hour.

Rules correctly tailored to the market
In October, the Chicago Mercantile Exchange traded 34m eurodollar contracts, 22.9m futures contracts in 10-year notes, and 9.4m futures contracts in 5-year notes. Turnover on the New York Stock Exchange exceeds 1bn shares a day.

In these highly-liquid, standardized markets, real-time reporting and price transparency are meaningful concepts. When these concepts are applied to the OTC markets, adjustments should be made, especially given the fact that many of these low-frequency transactions have large notionals and need to be hedged discreetly to minimize hedging costs.

Also there are many non-G14 institutions that only trade a handful of new transactions per week or month; and real-time reporting would impose a cost which is disproportionate to the benefit to be achieved.

Certainly, there needs to be more transparency in the OTC markets and the current legislation and rule-making is moving the market in the right direction. However it is important for the new rules to reflect the realities of the market so regulators and the public have access to meaningful information. Intra-day reporting will place systems and cost burdens on institutions already restructuring to meet the demands of new legislation and regulation, and will not yield significant results to the public.

* The G-14 financial institutions include: Bank of America-Merrill Lynch, Barclays Capital, BNP Paribas, Citi, Credit Suisse, Deutsche Bank, Goldman Sachs, HSBC, J.P. Morgan, Morgan Stanley, The Royal Bank of Scotland Group, Société Générale, UBS, Wells Fargo Bank.







Please enter your full name.

Disclaimer
Interest Rate Trade Reporting Repository
Terms and Conditions for Access and Use


1. Scope of Agreement
    These terms and conditions (this "Agreement") govern your access to and use of any public repository reports of OTC interest rate derivatives (each a "Report") produced by TriOptima AB ("TriOptima"), as described on the information web page regarding the repository. You must accept this Agreement to access and use Reports. You accept the Agreement by clicking the "I Agree" button on the bottom of this page. TriOptima may at any time, without advance or specific notice, amend this Agreement. Hence, you are expected to review and accept this Agreement each time you wish to access any Report through this website.


2. Intellectual property rights, license to use
    You acknowledge that TriOptima is the sole and exclusive owner of any and all intellectual property rights to the structure and layout of any Report.


    TriOptima hereby grants to you a non-exclusive license to use Reports in accordance with this Agreement.


3. Prohibited use of Reports
    You must not use any Report or the information contained in any Report in a manner that may harm or be detrimental to TriOptima, including without limitation, to use any Report to directly or indirectly compete or promote competition with TriOptima.


    You are not allowed to use TriOptima's name or any trademarks, trade names or service marks contained in any Report or this website in advertising, publicity or otherwise; neither are you allowed to copy any marks, specific characteristics or attributes of any Report for any other purpose than for making a lawful and contractually permitted copy of a Report.


4. Non-reliance, no warranty, disclaimer
    Each Report is provided to you free of charge. However, TriOptima does not warrant or undertake to make any Reports available to you; hence you acknowledge that TriOptima, in its sole discretion, may or may not make Reports available to you via this website or otherwise.


    Each Report is intended for information purposes only. Any information in a Report may at any time be superseded or replaced by new or updated information. Furthermore, the information contained in a Report is based on the information submitted by third parties for the purpose of inclusion in such Report. The information contained in a Report is neither checked, nor verified by TriOptima. Consequently, you acknowledge that Reports are for information purposes only, that they may not be relied upon for any purpose whatsoever, and that they are dependent upon, as regards their accuracy and completeness, the data submitted to TriOptima by third parties.


    The parties acknowledge that TriOptima makes no representation or warranty with respect to any Report or this website or any data or materials retrieved, obtained, provided or transmitted, by or to you, using this website. Each Report and this website and all such data and materials are being provided to you "as is". TriOptima hereby disclaims any and all representations and warranties, whether express or implied, including without limitation, any representation or warranty as to merchantability or fitness for a particular purpose, any representations or warranties arising from course of dealing or course of performance, and any representations or warranties of accuracy, reliability or functionality.


    To the maximum extent permitted by law, TriOptima disclaims all liability arising out of or in connection with the use of any Report or this website.

    Without prejudice to the above, TriOptima shall not be liable to you, or anyone claiming under or through you, for loss of profit, or any indirect or consequential loss or damages under or in connection with this Agreement, the use of any Report or this website, including without limitation, damages for loss of capital, interest, revenue, data or use, or interruption of business, even if you had been advised of the possibility of such damages.


    Notwithstanding anything to the contrary in this Agreement, TriOptima does not exclude or limit its liability for wilful misconduct, fraud or death or personal injury arising from TriOptima's negligence.


    For purposes of this clause, references to TriOptima shall be deemed to include its affiliates and their respective partners, officers, employees, directors, agents, contractors, representatives, successors and assigns.


5. Viruses, malware
    To the best of TriOptima's knowledge, Reports published on this website, this website and the server on which it resides are free from viruses and other malware. However, TriOptima cannot warrant this to be the case, and it is your responsibility to take precautions to prevent your computer and/or network to be affected by viruses or other malware. Hence, TriOptima does not assume any liability for any damage or loss, whether direct or indirect, including loss of data, caused to you by viruses or other malware from Reports published on this website, this website or the server on which it resides, including when you download any Report.


6. Applicable law, disputes
    This Agreement and any non-contractual obligations arising in connection with it shall be governed by English law, without regard to its principles of conflicting laws. Each party submits to the exclusive jurisdiction of the English courts for all purposes relating to this Agreement (including the enforcement of any determinations).
I agree    I decline